Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Mechanism of Cardiac Arrhythmias

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Lipoxin A 4 (LXA 4 ) for diabetic retinopathy (DR).

Indian journal of ophthalmology·2026

Same author

Effect of essential fatty acids (EFAs) and their metabolites on the growth suppressive action of anti-cancer drug doxorubicin on neuro- and glioblastoma cells in vitro.

Prostaglandins & other lipid mediators·2026

Same author

Arachidonic Acid and Lipoxin A4 Protect Pancreatic β-Cells and Improve Hyperglycemia Induced by Bleomycin.

Journal of biochemical and molecular toxicology·2026

Same author

Is Sepsis an Essential Fatty Acids Deficiency State?

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine·2025

Same author

Why vitamin C and corticosteroids are inadequate and how essential fatty acids (EFAs) can augment recovery from sepsis.

Nutrition (Burbank, Los Angeles County, Calif.)·2025

Same author

Arachidonic Acid Protects Skeletal Muscle Against Hyperglycaemia-Induced Muscle Atrophy by Modulating Myogenesis and Regulating KLF15 Expression in C57Bl/6 Mice.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2025

Search research articles

Related Experiment Video

Updated: Jun 8, 2026

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

Lipoxin A4 may function as an endogenous anti-arrhythmic molecule.

Undurti N Das¹

¹School of Biotechnology, Jawaharlal Nehru Technological University, Kakinada 533 003, India. Undurti@hotmail.com

Medical Hypotheses

|September 14, 2010

Summary

Omega-3 fatty acids like eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) may prevent cardiac arrhythmias. Their metabolites, including lipoxins, resolvins, and protectins, show potential as novel anti-arrhythmic therapies.

More Related Videos

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

Related Experiment Videos

Last Updated: Jun 8, 2026

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology

Published on: September 13, 2022

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

Area of Science:

Cardiology
Molecular Biology
Biochemistry

Background:

Cardiac arrhythmias are a major cause of death in patients with cardiovascular diseases.
Inflammation, oxidative stress, and fibrosis contribute to arrhythmia development, particularly atrial fibrillation.
Myeloperoxidase (MPO) activity from leukocytes can promote myocardial fibrosis and arrhythmias.

Purpose of the Study:

To investigate the role of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in preventing cardiac arrhythmias.
To explore the anti-inflammatory and anti-fibrotic mechanisms of EPA and DHA metabolites.
To propose novel therapeutic strategies for cardiac arrhythmias based on these findings.

Main Methods:

Review of existing literature on cardiac arrhythmias, inflammation, and omega-3 fatty acids.
Analysis of the biochemical pathways involving EPA, DHA, and their lipid mediators.
Hypothesizing the role of lipoxins, resolvins, and protectins in modulating MPO activity and fibrosis.

Main Results:

EPA and DHA supplementation has been shown to suppress cardiac arrhythmias.
These fatty acids are precursors to anti-inflammatory and anti-fibrotic lipid molecules (lipoxins, resolvins, protectins, maresins).
These molecules inhibit MPO activity and reduce myocardial damage and fibrosis.

Conclusions:

Deficiency in EPA and DHA may lead to increased inflammation and MPO activity, promoting arrhythmias.
Lipoxins, resolvins, and protectins may act as endogenous anti-arrhythmic agents.
Synthetic analogs of these molecules hold promise for managing cardiac arrhythmias.